Sale!

ARL11 Gene Tumor Predisposition Syndrome ARL11 Related Genetic Test Cost

Original price was: 5,600 د.إ.Current price is: 4,400 د.إ.

-21%

ARL11 Gene Tumor Predisposition Syndrome is a rare genetic condition linked to an increased risk of developing various types of tumors. The condition is associated with mutations in the ARL11 gene, which plays a crucial role in the regulation of cell growth and apoptosis. Individuals carrying mutations in this gene may be predisposed to a higher risk of cancer, making early detection and monitoring essential for managing their health.

The ARL11 Related Genetic Test is a specialized diagnostic tool designed to identify mutations in the ARL11 gene. This test is crucial for individuals with a family history of cancer or those who are at an increased risk of developing tumors associated with the ARL11 gene mutation. By detecting these mutations, the test can provide valuable information that helps in the early diagnosis, targeted treatment, and management of the condition, potentially improving the patient’s prognosis.

This genetic test is available at DNA Labs UAE, a leading facility known for its advanced genetic testing services. The cost of the ARL11 Related Genetic Test is 4400 AED. DNA Labs UAE employs state-of-the-art technology and follows stringent protocols to ensure the accuracy and reliability of the test results. Opting for this test at DNA Labs UAE not only offers individuals a chance to take proactive steps towards managing their health but also provides them with the support of highly skilled professionals throughout the testing process.

Description

ARL11 Gene Tumor Predisposition Syndrome

Test Name: ARL11 Gene Tumor Predisposition Syndrome – ARL11 related Genetic Test

Test Components: ARL11 gene mutation analysis

Price: 4400.0 AED

Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card

Report Delivery: 3 to 4 Weeks

Method: NGS Technology (Next-Generation Sequencing)

Test Type: Cancer

Doctor: Oncologist

Test Department: Genetics

Pre Test Information: Clinical History of Patient who is going for ARL11 Gene Tumor predisposition syndrome, ARL11 related NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with ARL11 Gene Tumor predisposition syndrome, ARL11 related NGS Genetic DNA Test gene ARL11

Test Details:

ARL11 gene tumor predisposition syndrome is a genetic disorder caused by mutations in the ARL11 gene. This syndrome is characterized by an increased risk of developing various types of tumors, including breast, ovarian, pancreatic, and colorectal cancers.

NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that allows for the analysis of multiple genes simultaneously. In the context of ARL11 gene tumor predisposition syndrome, NGS genetic testing can be used to identify mutations in the ARL11 gene, which can help in the diagnosis and management of individuals at risk for this syndrome.

NGS genetic testing involves sequencing the DNA of an individual to identify specific genetic variations or mutations. This technique enables the analysis of multiple genes simultaneously, providing a comprehensive view of an individual’s genetic makeup.

The results of ARL11-related NGS genetic testing can help identify individuals who are at an increased risk of developing tumors associated with ARL11 gene mutations. This information can be used for early detection, surveillance, and personalized management strategies, such as increased screening or preventive measures.

It is important to note that genetic testing for ARL11 gene tumor predisposition syndrome is typically recommended for individuals with a family history of tumors associated with this syndrome or those who meet specific clinical criteria. Genetic counseling is often recommended before and after genetic testing to help individuals understand the implications of the results and make informed decisions about their healthcare.

Test Name	ARL11 Gene Tumor predisposition syndrome ARL11 related Genetic Test
Components
Price	4400.0 AED
Sample Condition	Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery	3 to 4 Weeks
Method	NGS Technology
Test type	Cancer
Doctor	Oncologist
Test Department:	Genetics
Pre Test Information	Clinical History of Patient who is going for ARL11 Gene Tumor predisposition syndrome, ARL11 related NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with ARL11 Gene Tumor predisposition syndrome, ARL11 related NGS Genetic DNA Test gene ARL11
Test Details	ARL11 gene tumor predisposition syndrome is a genetic disorder caused by mutations in the ARL11 gene. This syndrome is characterized by an increased risk of developing various types of tumors, including breast, ovarian, pancreatic, and colorectal cancers. NGS (Next-Generation Sequencing) genetic testing is a type of genetic testing that allows for the analysis of multiple genes simultaneously. In the context of ARL11 gene tumor predisposition syndrome, NGS genetic testing can be used to identify mutations in the ARL11 gene, which can help in the diagnosis and management of individuals at risk for this syndrome. NGS genetic testing involves sequencing the DNA of an individual to identify specific genetic variations or mutations. This technique enables the analysis of multiple genes simultaneously, providing a comprehensive view of an individual’s genetic makeup. The results of ARL11-related NGS genetic testing can help identify individuals who are at an increased risk of developing tumors associated with ARL11 gene mutations. This information can be used for early detection, surveillance, and personalized management strategies, such as increased screening or preventive measures. It is important to note that genetic testing for ARL11 gene tumor predisposition syndrome is typically recommended for individuals with a family history of tumors associated with this syndrome or those who meet specific clinical criteria. Genetic counseling is often recommended before and after genetic testing to help individuals understand the implications of the results and make informed decisions about their healthcare.